Daiichi Sankyo adds $484M pact to its ongoing Zymeworks collaboration; Surface spins out of Imprimis with $20M raise
→ After working with Zymeworks as a partner over the past two years, Daiichi Sankyo has come back for more, paying $18 million upfront and promising $466.7 million more for licenses to develop two more assets. Vancouver-based Zymeworks has scored a number of partnership deals with big players — think Celgene and J&J — with Azymetric, its platform tech which transforms monospecific antibodies into bispecific antibodies.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
